These highlights do not include all the information needed to use ALBUMIN (HUMAN) 5% safely and effectively. See full prescribing information for ALBUMIN (HUMAN) 5%. ALBUMIN (HUMAN) 5% For intravenous use only 5% solution Initial U.S. Approval: 2 | Albumin (Human)

05:56 EDT 27th August 2014 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

ALBUMIN (HUMAN) 5% is indicated in the emergency treatment of hypovolemia with or without shock. Its effectiveness in reversing hypovolemia depends largely upon its ability to draw interstitial fluid into the circulation. It is most effective in patients who are well hydrated. When blood volume deficit is the result of hemorrhage, compatible red blood cells or whole blood should be administered as quickly as possible. [1, 2]

ALBUMIN (HUMAN) 5% should be used when hydration is not adequate. When hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 20% - 25% albumin solutions should be used. [ 1 ]

For subjects with hypoalbuminemia who are critically ill and/or are bleeding actively, ALBUMIN (HUMAN) 5% infusions may be indicated.[ 3 ] When albumin deficit is the result of excessive protein loss, the effect of administration of ALBUMIN (HUMAN) 5% will be temporary unless the underlying disorder is reversed.

ALBUMIN (HUMAN) 5% may be used to maintain cardiovascular function following the removal of large volumes of ascitic fluid after paracentesis due to cirrhotic ascites. [ 2 ]

General Recommendations

The concentration of the albumin preparation, dosage and the infusion rate should be adjusted to the patient’s individual requirements.

The dose required depends on the body weight of the patient, the severity of trauma or illness and on continuing fluid and protein losses. Measures of adequacy of circulating volume and not plasma albumin levels should be used to determine the dose required. The daily dose should not exceed 2 g of ALBUMIN (HUMAN) 5% per kg of body weight.


In adults, an intravenous infusion of 25 g of ALBUMIN (HUMAN) 5% should be given. If adequate response (stabilization of circulation) is not achieved within 15 to 30 minutes, an additional dose may be given.

In spite of limited information about the efficacy in pediatric subjects, an intravenous infusion of 2.5 to 12.5 g or 0.5 to 1 g/kg body weight may be given. If adequate response (stabilization of circulation) is not achieved within 15 to 30 minutes, an additional dose may be given.

Hemodilution may follow administration of ALBUMIN (HUMAN) 5%. If hemorrhage has occurred, this may result in relative anemia. This condition should be controlled by the supplemental administration of compatible red blood cells or compatible whole blood.


In adults, intravenous infusion of 50 to 75 g of ALBUMIN (HUMAN) 5% may be used. Hypoalbuminemia is usually accompanied by a hidden extravascular albumin deficiency of equal magnitude. This total body albumin deficit must be considered when determining the amount of albumin necessary to reverse the hypoalbuminemia.

In burns, therapy usually starts with the administration of large volumes of crystalloid injection to maintain plasma volume. After 24 hours, ALBUMIN (HUMAN) 5% may be added at an initial dose of 25 g with the dose adjusted thereafter to maintain a plasma protein concentration of 2.5 g per 100 mL or a serum protein concentration of 5.2 g/100 mL.

Prevention of Central Volume Depletion after Paracentesis due to Cirrhotic Ascites

In adults, intravenous infusion of 8 g of ALBUMIN (HUMAN) 5% may be given for every 1,000 mL of ascitic fluid removed.

Intravenous use only.

Prior to administration, parenteral drug products should be inspected visually for turbidity and discoloration, whenever solution and container permit.

Do not dilute with sterile water for injection.

Do not use solutions of ALBUMIN (HUMAN) 5% which are cloudy or have deposits. Once the infusion container has been opened the contents should be used immediately. Discard the unused portion. Filtration of ALBUMIN (HUMAN) 5% is not required.

The infusion rate should be adjusted according to the individual circumstances and the indication. In plasma exchange during paracentesis, the infusion rate may be higher and should be adjusted to the rate of removal.

If large volumes (greater than 1500 ml) are administered, the product should be warmed to room temperature before use.

ALBUMIN (HUMAN) 5% is supplied in

Do not use in individuals who are hypersensitive to albumin preparations, any ingredient in the formulation, or components of the container.

Hypersensitivity or allergic reactions have been observed, and may in some cases progress to severe anaphylaxis. Epinephrine should be available immediately to treat any acute hypersensitivity reaction.

Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the patient’s volume status. At the first clinical signs of possible cardiovascular overload, e.g., headache, dyspnea, increased blood pressure, jugular venous distention, elevated central venous pressure, pulmonary edema, the infusion should be stopped immediately and the patient reevaluated. Albumin should be used with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk for the patient. Examples of such conditions are:

When albumin is given, monitor the electrolyte status of the patient and take appropriate steps to restore or maintain the electrolyte balance.

If comparatively large volumes are to be replaced, monitoring of coagulation and hematocrit is necessary. Ensure adequate substitution of other blood constituents (coagulation factors, electrolytes, platelets and erythrocytes).

If ALBUMIN (HUMAN) 5% is to be administered, monitor hemodynamic performance regularly; this may include:

ALBUMIN (HUMAN) 5% must not be diluted with sterile water for injection as this may cause hemolysis in recipients.

This product is a derivative of human plasma. Based on effective donor screening and product manufacturing processes it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob Disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have been identified for ALBUMIN (HUMAN) 5%.

The most serious events are anaphylactic shock, circulatory failure, cardiac failure, and pulmonary edema.

The most common adverse events are anaphylactoid type of reactions.

Adverse reactions for ALBUMIN (HUMAN) 5% normally resolve when the infusion rate is slowed down or the infusion is stopped. In case of severe reactions, the infusion should be stopped and appropriate treatment should be initiated.

No clinical studies were done using ALBUMIN (HUMAN) 5%.

The following adverse reactions have been identified during post-approval use of ALBUMIN (HUMAN) (any strength). Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency.

Table 1 Adverse reactions observed for ALBUMIN HUMAN (any strength) during post-marketing phase (in decreasing order of severity)

Observed Adverse Reactions
anaphylactic shock
cardiac failure
loss of consciousness
circulatory failure
congestive heart failure
pulmonary edema
angioneurotic edema
rash erythematous
confusional state

No drug interaction studies have been conducted.

Pregnancy Category C. Animal reproduction studies have not been performed with ALBUMIN (HUMAN) 5%. It is also not known whether ALBUMIN (HUMAN) 5% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. ALBUMIN (HUMAN) 5% should be given to a pregnant woman only if necessary.

It is also not known whether ALBUMIN (HUMAN) 5% can cause fetal harm when administered to a woman during labor or delivery or if it will affect reproductive capacity. ALBUMIN (HUMAN) 5% should be given during labor or delivery only if necessary.

It is not known whether this drug is excreted in human milk. ALBUMIN (HUMAN) 5% should be given to nursing mothers only if necessary. Because many drugs are excreted in human milk, caution should be exercised when ALBUMIN (HUMAN) 5% is administered to a lactating woman.

Data on the use of ALBUMIN (HUMAN) 5% in children including premature babies are very limited. The product should be administered to pediatric patients only if needed.

Clinical studies did not include a sufficient number of subjects aged 65 and older to determine whether they respond differently from younger subjects.

ALBUMIN (HUMAN) 5% is a sterile, liquid preparation of albumin derived from large pools of human plasma. All units of human plasma used in the manufacture of ALBUMIN (HUMAN) 5% are provided by FDA approved blood establishments only.

The product is manufactured by cold ethanol fractionation followed by ultra- and diafiltration. The manufacturing process includes final container pasteurization and additional bulk pasteurization at 60 +/- 0.5°C for 10 – 11 hours. The ALBUMIN (HUMAN) 5% manufacturing process provides a significant viral reduction in in vitro studies (table 2). These reductions are achieved through a combination of process steps including Cohn fractionation and final container pasteurization.

No procedure, however, has been shown to be completely effective in removing viral infectivity from derivatives of human plasma. [see Warnings and Precautions, Infection Risk from Human Plasma (5.7)]

Table 2 In vitro reduction factor during ALBUMIN (HUMAN) 5% manufacturing

PRV: Pseudorabies Virus

SBV: Sindbis Virus

HIV-1: Human Immunodeficiency Virus - 1

Reo 3: Reovirus Type 3

PPV: Porcine Parvovirus

HAV: Hepatitis A Virus

ALBUMIN (HUMAN) 5% is a clear, slightly viscous liquid; it is almost colorless or slightly yellow or green.

The composition of ALBUMIN (HUMAN) 5% is as follows:

ALBUMIN (HUMAN) 5% contains no preservatives and components used in its packaging are latex-free.

IMAGE img0001.jpg
Component Quantity/1000 ml
Protein, of which greater than or equal to
96% is human albumin 50 g
Sodium 130 – 160 mmol
Potassium less than or equal to 2 mmol
N-acetyl-DL-tryptophan 0.064 - 0.096 mmol/g protein
Caprylic acid 0.064 - 0.096 mmol/g protein
Water for Injection ad. 1000 ml

No pharmacokinetic or pharmacodynamic studies with ALBUMIN (HUMAN) 5% have been conducted.

Albumin is responsible for 75-80% of the colloid osmotic pressure of normal plasma. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. [ 3 ]

Albumin is a protein with a total extravascular mass of approximately 160 g and an intravascular mass of about 120 g. [ 3 ]

Albumin (Human) 5% is approximately isotonic and iso-oncotic with normal human plasma. When treating patients with diminished blood volume, the effect of infused albumin may persist for many hours. The hemodilution lasts for a shorter time when albumin is administered to individuals with normal blood volume. [ 4 ]

No non-clinical toxicology studies with ALBUMIN (HUMAN) 5% have been conducted. Human Albumin is a normal constituent of human plasma and acts like physiological albumin.

No clinical studies with ALBUMIN (HUMAN) 5% have been conducted.

ALBUMIN (HUMAN) 5% is supplied in 5.0 g in 100 mL, 12.5 g in 250 mL or 25.0 g in 500 mL single use bottles.

ALBUMIN (HUMAN) 5% may be stored for 36 months at +2°C to + 25°C (36°F to 77°F) from the date of manufacture.

Store protected from light.

Do not freeze.

Do not use after expiration date.

Do not use if turbid.

NDC Number NDC Number Size Grams protein
Octapharma Pharmazeutika Produktionsges.m.b.H Octapharma AB
67467-623-01 68209-623-01 100 ml 5.0
67467-623-02 68209-623-02 250 ml 12.5
67467-623-03 68209-623-03 500 ml 25.0

This product is usually given in a hospital setting.

Inform patients being treated with Albumin (Human) 5% about the potential risks and benefits with its use [see Adverse Reactions (6)]. Discontinue immediately if allergic symptoms occur (e.g. skin rashes, hives, itching, breathing difficulties, coughing, nausea, vomiting, fall in blood pressure, increased heart rate).

Inform patients that ALBUMIN (HUMAN) 5% is a derivative of human plasma and may contain infectious agents that cause disease (e.g., viruses, and theoretically, CJD agent). Inform patients that the risk that ALBUMIN (HUMAN) 5% may transmit an infections agent has been reduced by screening plasma donors for prior exposure for certain viruses, by testing the donated plasma for certain virus infections and by inactivating and/or removing certain viruses during manufacturing [see Warnings and Precautions (5.7)].

Manufactured by:

Octapharma Pharmazeutika Produktionsges.m.b.H.

Oberlaaer Strasse 235

A-1100 Vienna, Austria

Octapharma AB

Elersvägen 40

SE- 112 75, Sweden

U.S. License No. 1646

Distributed by:

Octapharma USA Inc.

121 River Street, 12 floor

Hoboken, NJ 07030


Albumin (Human) 5%

5 g in 100 mL

Octapharma Pharmazeutika Produktionsges.m.b.H

NDC 67467-623-01


Albumin (Human) 5%

12.5 g in 250 mL

Octapharma Pharmazeutika Produktionsges.m.b.H

NDC 67467-623-02


Albumin (Human) 5%

25 g in 500 mL

Octapharma Pharmazeutika Produktionsges.m.b.H

NDC 67467-623-03

IMAGE img0002.jpgIMAGE img0003.jpgIMAGE img0004.jpg


Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.

Active Ingredients


Drugs and Medications [28 Associated Drugs and Medications listed on BioPortfolio]

Human albumin grifols [Instituto Grifols, S.A.]

Albumin (Human) U.S.P. Human Albumin Grifols 25%

Human albumin grifols [Instituto Grifols, S.A.]

Albumin (Human) U.S.P. Human Albumin Grifols 20%

Albutein [Grifols Biologicals Inc.]

These highlights do not include all the information needed to use Albutein 5% safely and effectively. See full prescribing information for Albutein 5%. Albutein 5% [Albumin (Human) U.S.P.] sterile, aq...

Albumin (human) [Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.]

These highlights do not include all the information needed to use ALBUMIN (HUMAN) 20% safely and effectively. See full prescribing information for ALBUMIN (HUMAN) 20%. ALBUMIN (HUMAN) 20% For intraven...

Alburx [CSL Behring AG]

AlbuRx 5 Albumin (Human) 5% Solution

Clinical Trials [2216 Associated Clinical Trials listed on BioPortfolio]

Voluven® in Paediatric Patients

This study will compare the clinical efficacy and safety of Voluven® and Human Albumin during elective open-heart surgery in pediatric patients.

The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome

This research study was designed to look at the effect of human albumin transfusion on circulating levels of Vascular Endothelial Derived Growth Factor (VEGF), a protein that is believed t...

Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations

This is a prospective, randomized, controlled study to determine if albumin and propofol or albumin only will provide superior qualitative contrast enhancement during TEE bubble studies co...

Treatment of Subarachnoid Hemorrhage With Human Albumin

The purpose of this study is to evaluate the tolerability and safety of 25 percent human albumin therapy in patients with subarachnoid hemorrhage.

Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients

Primary purpose : mortality at Day 28 Secondary purposes : - Daily SOFA (Sequential Organ Failure Assessment) score lessening within Intensive Care Unit (ICU) - D...

PubMed Articles [12032 Associated PubMed Articles listed on BioPortfolio]

Human Albumin Use in Adults in U.S. Academic Medical Centers.

To determine rates and predictors of albumin administration, and estimated costs in hospitalized adults in the United States.

Interaction of α-synuclein with Rhus typhina tannin - Implication for Parkinson's disease.

The etiology of Parkinson's disease (PD) relates to α-synuclein, a small protein with the ability to aggregate and form Lewy bodies. One of its prevention strategies is inhibition of α-synuclein oli...

Chemical-defined and albumin-free generation of human atrial and ventricular myocytes from human pluripotent stem cells.

Most existing culture media for cardiac differentiation of human pluripotent stem cells (hPSCs) contain significant amounts of albumin. For clinical transplantation applications of hPSC-derived cardio...

Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells.

5-Fluorouracil (5-FU) is a first-line chemotherapeutic drug in colorectal cancer. However, intravenous administration of 5-FU at the dose of 7-12mg/kg exhibits curbs like short half-life (20min) and t...

Non-enzymatic glucosylation induced neo-epitopes on human serum albumin: A concentration based study.

Hyperglycaemia induced non enzymatic glycation is accelerated in diabetic patients and aggressively involved in diabetes progression. Human serum albumin (HSA) is the most abundant protein in blood ci...

Quick Search

Relevant Topics

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record